The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

There's a need for early anti-tumor necrosis factor (TNF) therapy in inflammatory bowel disease (IBD), with new data showing ...

Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the ...

Starjemza gains FDA approval as the eighth ustekinumab biosimilar, enhancing treatment options for rheumatic and gastrointestinal conditions.

In conclusion, the 2025 CDSCO draft guidelines represent a meaningful and commendable step toward global regulatory alignment ...

Eculizumab biosimilars could provide European patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic ...

Holz, MD, discussed the rationale and safety surrounding the automatic substitution of biosimilars at the pharmacy level, as well as common misconceptions about these medications.

Number 5: Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained ...

Number 5: Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs and expanding treatment access. Number 4: Australia’s growing ...